drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Chimeric IgG1 monoclonal antibody against endoglin (CD105), a TGF-β coreceptor on proliferating tumor endothelium; inhibits TGF-β/SMAD–mediated angiogenesis, may induce ADCC, and interferes with VEGF cross-talk.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Carotuximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody targeting endoglin (CD105) on proliferating tumor endothelium; blocks endoglin-mediated TGF-β/SMAD signaling and VEGF cross-talk to inhibit angiogenesis, and can engage Fc-mediated ADCC against CD105+ endothelial cells.
drug_name
Carotuximab (TRC105)
nct_id_drug_ref
NCT05534646